Nadine Van Roy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7298920/publications.pdf

Version: 2024-02-01

		236925	155660
65	3,337	25	55
papers	citations	h-index	g-index

69	69	69	4673
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Extrauterine Mesonephric-like Neoplasms. American Journal of Surgical Pathology, 2022, 46, 124-133.	3.7	26
2	The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples. European Journal of Cancer, 2022, 160, 12-23.	2.8	16
3	Malignant pleural mesothelioma with an EML4-ALK fusion: Expect the unexpected!. Pathology Research and Practice, 2022, 231, 153772.	2.3	4
4	Minimally invasive classification of paediatric solid tumours using reduced representation bisulphite sequencing of cell-free DNA: a proof-of-principle study. Epigenetics, 2021, 16, 196-208.	2.7	23
5	Development of chronic myeloid leukemia in a patient previously diagnosed with a JAK2-positive myeloproliferative neoplasm. Clinical Chemistry and Laboratory Medicine, 2021, 59, e392-e394.	2.3	2
6	Association of unbalanced translocation der(1;7) with germline GATA2 mutations. Blood, 2021, 138, 2441-2445.	1.4	12
7	From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma. Journal of Personalized Medicine, 2021, 11, 1286.	2.5	2
8	Detection of Copy Number Alterations by Shallow Whole-Genome Sequencing of Formalin-Fixed, Paraffin-Embedded Tumor Tissue. Archives of Pathology and Laboratory Medicine, 2020, 144, 974-981.	2.5	6
9	The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review. European Journal of Pediatrics, 2020, 179, 191-202.	2.7	55
10	Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. Journal of Clinical Oncology, 2020, 38, 3685-3697.	1.6	9
11	Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. Blood, 2020, 135, 1685-1695.	1.4	28
12	Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. Haematologica, 2019, 104, e17-e20.	3.5	18
13	A case of chronic eosinophilic leukemia with secondary transformation to acute myeloid leukemia. Leukemia Research Reports, 2018, 9, 45-47.	0.4	2
14	Tandem repeats of Allium fistulosum associated with major chromosomal landmarks. Molecular Genetics and Genomics, 2017, 292, 453-464.	2.1	52
15	The challenging differential diagnosis of skin tumours with a rhabdoid phenotype: not all tumours with rhabdoid phenotype belong to the group of <scp>SMARCB</scp>1â€deficient tumours. Histopathology, 2016, 68, 608-612.	2.9	0
16	Monosomy 22 and partial loss of INI1 expression in a biphasic synovial sarcoma with an Ewing sarcoma-like poorly differentiated component: Report of a case. Pathology Research and Practice, 2016, 212, 658-664.	2.3	1
17	Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia. Oncotarget, 2016, 7, 73769-73780.	1.8	30
18	Towards a FISH-based karyotype of Rosa L. (Rosaceae). Comparative Cytogenetics, 2016, 10, 543-554.	0.8	21

#	Article	IF	Citations
19	Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. Blood, 2015, 126, 1575-1584.	1.4	69
20	ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. Nature Communications, 2015, 6, 5794.	12.8	75
21	Molecular basis and clinical significance of genetic aberrations in B-cell precursor acute lymphoblastic leukemia. Experimental Hematology, 2015, 43, 640-653.	0.4	20
22	Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment. Clinical Cancer Research, 2015, 21, 3327-3339.	7.0	76
23	CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol. Haematologica, 2015, 100, 1311-1319.	3.5	8
24	Anchoring Linkage Groups of the Rosa Genetic Map to Physical Chromosomes with Tyramide-FISH and EST-SNP Markers. PLoS ONE, 2014, 9, e95793.	2.5	27
25	Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. Nature Communications, 2014, 5, 4767.	12.8	421
26	Prognostic Relevance of CD200/Btla Deletions in Pediatric Precursor-B Cell Acute Lymphoblastic Leukemia Treated According to the EORTC-CLG 58951 Protocol. Blood, 2014, 124, 2394-2394.	1.4	0
27	Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes. PLoS ONE, 2013, 8, e52321.	2.5	37
28	Regulatory Networks Governed by MicroRNAs in T-ALL Oncogenesis and Normal T-Cell Development. Blood, 2011, 118, 1366-1366.	1.4	0
29	Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification. Clinical Cancer Research, 2010, 16, 4353-4362.	7.0	243
30	The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy. Genome Medicine, 2009, 1, 74.	8.2	34
31	Downregulation of MiR-449a Is Essential for the Survival of EVI1 Positive Leukemic Cells through Modulation of NOTCH1 and BCL2.. Blood, 2009, 114, 361-361.	1.4	0
32	Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics. International Journal of Cancer, 2008, 122, 1177-1182.	5.1	22
33	MicroRNA Profiling of EVI1 Deregulated Myeloid Leukemia. Blood, 2008, 112, 5322-5322.	1.4	0
34	MicroRNA signatures in Genetic Subtypes of T-Cell Acute Lymphoblastic Leukemia.. Blood, 2008, 112, 3360-3360.	1.4	1
35	Comparison of miRNA Profiles of Microdissected Hodgkin/Reed-Sternberg Cells and Hodgkin Cell Lines Versus CD77+ B-Cells Reveals a Distinct Subset of Differentially Expressed miRNAs. Blood, 2008, 112, 4488-4488.	1.4	0
36	Improved Detection of Chromosomal Abnormalities in CLL by Conventional Cytogenetics Using CpG Oligonucleotide and Interleukin-2 Stimulation. A Belgian Multicentric Study. Blood, 2008, 112, 3118-3118.	1.4	0

#	Article	IF	Citations
37	ArrayCGHâ€based classification of neuroblastoma into genomic subgroups. Genes Chromosomes and Cancer, 2007, 46, 1098-1108.	2.8	67
38	MicroRNA Profiling of EVI1 Deregulated Myeloid Leukemia.. Blood, 2007, 110, 4146-4146.	1.4	0
39	Translocationâ€“excisionâ€“deletionâ€“amplification mechanism leading to nonsyntenic coamplification of MYC and ATBF1. Genes Chromosomes and Cancer, 2006, 45, 107-117.	2.8	47
40	Unequivocal Delineation of Clinicogenetic Subgroups and Development of a New Model for Improved Outcome Prediction in Neuroblastoma. Journal of Clinical Oncology, 2005, 23, 2280-2299.	1.6	160
41	Evidence for involvement of a tumor suppressor gene on 1p in malignant peripheral nerve sheath tumors. Cancer Genetics and Cytogenetics, 2003, 143, 120-124.	1.0	7
42	Localization of the 17q breakpoint of a constitutional 1;17 translocation in a patient with neuroblastoma within a 25-kb segment located between theACCN1 andTLK2 genes and near the distal breakpoints of two microdeletions in neurofibromatosis type 1 patients. Genes Chromosomes and Cancer, 2002, 35, 113-120.	2.8	21
43	Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: How many genetic subgroups are there?. Medical and Pediatric Oncology, 2001, 36, 5-10.	1.0	82
44	Frequent allelic loss at 10q23 but low incidence ofPTEN mutations in merkel cell carcinoma. International Journal of Cancer, 2001, 92, 409-413.	5.1	63
45	Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines. Genes Chromosomes and Cancer, 2001, 32, 126-135.	2.8	46
46	Molecular cytogenetic and clinical findings inETV6/ABL1-positive leukemia. Genes Chromosomes and Cancer, 2001, 30, 274-282.	2.8	103
47	Molecular cytogenetic and clinical findings in ETV6ABL1â€positive leukemia. Genes Chromosomes and Cancer, 2001, 30, 274-282.	2.8	3
48	Subtelomeric familial translocation t(2;7)(q37;q35) leading to partial trisomy 7q35?qter: Molecular cytogenetic analysis and clinical phenotype in two generations. American Journal of Medical Genetics Part A, 2000, 93, 349-354.	2.4	24
49	Chromosome 2 short arm translocations revealed by M-FISH analysis of neuroblastoma cell lines. Medical and Pediatric Oncology, 2000, 35, 538-540.	1.0	17
50	Exhaustive mutation analysis of theNF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Human Mutation, 2000, 15, 541-555.	2.5	477
51	Structure and mutation analysis of the gene encoding DNA fragmentation factor 40 (caspase-activated) Tj ETQq1 1 0.784314 rgBT /Ov	3.8	28
52	Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. , 2000, 15, 541.		4
53	Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Human Mutation, 2000, 15, 541.	2.5	6
54	Gain of Chromosome Arm 17q and Adverse Outcome in Patients with Neuroblastoma. New England Journal of Medicine, 1999, 340, 1954-1961.	27.0	456

#	Article	IF	Citations
55	Cytogenetic and molecular analysis of cellular atypical mesoblastic nephroma. , 1998, 21, 265-269.		16
56	Molecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cell lines. , 1998, 23, 116-122.		36
57	Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes and Cancer, 1998, 23, 141-152.	2.8	121
58	Monosomy 22 in a mixed germ cell-sex cord-stromal tumor of the ovary. Genes Chromosomes and Cancer, 1997, 19, 192-194.	2.8	18
59	Balanced translocation in a neuroblastoma patient disrupts a cluster of small nuclear RNA UI and tRNA genes in chromosomal band Ip36. Genes Chromosomes and Cancer, 1995, 14, 35-42.	2.8	22
60	Identification of two distinct chromosome 12-derived amplification units in neuroblastoma cell line NGP. Cancer Genetics and Cytogenetics, 1995, 82, 151-154.	1.0	43
61	Molecular cytogenetic analysis of a familial pericentric inversion of chromosome 12. Clinical Genetics, 1993, 44, 156-163.	2.0	12
62	Reciprocal translocation between the proximal regions of the long arms of chromosomes 13 and 15 resulting in unbalanced offspring: characterization by fluorescence in situ hybridization and DNA analysis. Human Genetics, 1992, 89, 407-413.	3.8	5
63	Molecular cytogenetic analysis of a complex t(10;22;11) translocation in ewing's sarcoma. Genes Chromosomes and Cancer, 1992, 4, 188-191.	2.8	17
64	Is t(6;20)(p21;q13) a characteristic chromosome change in endometrial polyps?. Genes Chromosomes and Cancer, 1991, 3, 318-319.	2.8	20
65	Pallister-killian syndrome: Characterization of the isochromosome 12p by fluorescentIn Situ hybridization. American Journal of Medical Genetics Part A, 1991, 41, 381-387.	2.4	65